Acute myelogenous leukemia
Conditions
Interventions
Post-transplantation group of AML patients:NA
Sponsors
Medical Center of Hematology, the Second Affiliated Hospital of the Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: ? Acute Myeloid Leukemia (AML) diagnosed from March 2024 to March 2026 (intermediate-risk assessment according to NCCN), donors of both sexes, aged 18-50 years, with indications for transplantation and eligible for haploidentical hematopoietic stem cell transplantation. ?KPS score >60 points, predicted survival time >6 months; ? without serious damage of vital organs: ? creatinine 55%; ? heme >9g/dL, bilirubin 0.5×109/L, platelet >20×109/L); ? Stable control of primary blood diseases, no other contraindications of hematopoietic stem cell transplantation; ? Voluntarily participated in this study and signed informed consent.
Exclusion criteria
Exclusion criteria: ? There is active bleeding caused by drugs or thrombocytopenia; ? Pregnant or lactating women; ? Severe heart, kidney or liver dysfunction; ? combined with other malignant tumors requiring treatment; ? Inability to understand or follow the study protocol due to clinical symptoms of brain dysfunction or severe mental disease; ? patients who are unable to complete the necessary treatment plan and follow-up observation; ? patients with severe acute allergic reaction; ? clinical uncontrolled active infection; ? Investigators felt that other reasons were not appropriate for clinical trialists.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 10×Genomics Single Cell Transcriptome Sequencing;Co-profiling; Smart-seq3, based on Switching mechanism at the 5’end of the RNA template technology; | — |
Countries
China
Contacts
Public ContactXi Zhang
The Second Affiliated Hospital of the Army Medical University
Outcome results
None listed